1. Introduction {#s0005}
===============

Human mitochondrial (mt) diseases are a group of disorders due to mutations in nuclear or mt genes affecting mitochondrial functions.

A large proportion of these diseases is due to mutations in mt tRNA genes, resulting in the inhibition of mt protein synthesis and consequent OXPHOS defects, which can have variable severity, and for which at present no treatments exist. This absence is partly due to the scarcity of suitable models and to the fact that it is generally impossible to obtain site specific mitochondrial mutations. This difficulty has been overcome in yeast, in which biolistic mitochondrial transformation is possible ([@bb0010; @bb0030]).

Some years ago, we have established a yeast model of mitochondrial defects by introducing into yeast mt tRNA genes several base substitutions equivalent to those causing diseases in humans, and have observed that the consequent respiratory defects could be alleviated by overexpression of nuclearly encoded protein synthesis factors such as the mt protein elongation factor EF-Tu and the mt aminoacyl-tRNA synthetases (aaRS) ([@bb0015; @bb0020; @bb0025; @bb0070; @bb0075]).

Furthermore, we found that the same suppression of yeast defects could be obtained by the overexpression of the orthologous human factors ([@bb0075]).

Moreover, nuclear factors orthologous to those we had identified in yeast were found to have suppressing activity in patient cell lines and cybrids ([@bb0055; @bb0085; @bb0100; @bb0110]).

AaRS are evolutionarily important enzymes on which the fidelity of protein synthesis is based; to distinguish similar aminoacids some of them have editing domains which allow misacylation to be avoided; these and the other domains involved in aminoacylation and aminoacyl-adenylate formation have been extensively studied ([@bb0050; @bb0045; @bb0120]). In fungi, some aaRS domains also have a splicing function on mt introns ([@bb0040; @bb0090]).

Another important observation was that a point mutation in mt LeuRS strongly reducing the catalytic activity did not impair the suppression capability ([@bb0020]). Therefore we hypothesized that the suppressing function of aaRS might be exerted by protein regions involved in the interaction with tRNA, which might restore the correct structure of tRNA altered by the mutation in a sort of chaperon-like effect.

Isolated aaRS domains were subcloned in multicopy yeast vectors which were introduced into yeast mt tRNA mutants and examined for suppression capability.

We report here that the carboxy-terminal (C-terminal) region of human and yeast mt LeuRS has full suppressing activity. This domain is 66 (yeast) or 67 (human) aminoacids in length, so we investigated whether reduced peptides could maintain suppressing activities and hence possible therapeutic applications may be envisaged.

2. Materials and methods {#s0010}
========================

2.1. Strains, media and growth conditions {#s0015}
-----------------------------------------

*Saccharomyces cerevisiae* strains used are the WT MCC123 (MAT a, ade2, ura3-52, Δleu, kar1-1, Kan^R^, rho^+^) ([@bb0080]) and the isogenic *syn*^*−*^ mt mutants LeuC25T, ValC25T (bearing the same substitution in tRNA^Leu^ and tRNA^Val^ respectively), IleT32C and IleT33C ([@bb0025; @bb0020; @bb0075], and unpublished results). The IleT33C mutant showed no defective phenotype when mutated mitochondria were associated with the MCC123 nuclear context. Therefore we utilized a spore derivative showing a thermosensitive glycerol growth defect and the experiments were performed at the non permissive temperature.

The mutant strains were named with a three-letter code name of the aminoacid indicating the tRNA gene and the position of the base substitution referring to yeast cytoplasmic tRNA^Phe^ ([@bb0115]). The mutants were obtained by biolistic transformation: the required mutations in tRNA genes were created by site-directed mutagenesis following the procedure described in [@bb0095] and details can be found in [@bb0025] supplementary information.

Standard protocols ([@bb0105]) were used for *E. coli* and yeast transformations as well as plasmid preparations (see [Supplementary material for details](#ec0005){ref-type="supplementary-material"}).

Strains were grown in YP complete medium (1% yeast extract and 1% peptone from Difco) containing 3% glycerol or glucose (2% or 0.25%). To induce the Gal1 promoter in the suppression experiments, 0.1% galactose was added to YP 3% glycerol plates. Minimal medium was 0.7% yeast nitrogen base (Difco), 5% ammonium sulphate and 2% glucose, supplemented with the necessary auxotrophic requirements. For solid plates, 1.5% agar (Difco) was added to the aforementioned media.

2.2. Microscopy {#s0020}
---------------

GFP plasmids were used to observe the specific cellular localization of mt LeuRS and its variants. After transformation, the selected GFP clones were grown in 2% galactose supplemented with adenine (45 µg/ml). The late exponential culture was washed in YP liquid complete medium and the pellet suspended in growth media. One aliquot was fixed on glass slide and observed by fluorescent microscopy; another aliquot was treated with 1% formaldehyde for DAPI staining to control colocalization.

3. Results and discussion {#s0025}
=========================

We have previously used the biolistical methodology to introduce several human equivalent base substitutions into yeast mt tRNA genes. In particular we introduced mutations into tRNA^Leu^ UUR at positions: 14, 25, 60 (MELAS equivalent), 20 (MM/CPEO equivalent) and 29 (MMC equivalent). Mutations were also introduced into tRNA^Val^ at position 25, equivalent to the homoplasmic m. 1624 human mutation causing a syndrome with variable penetrance in the members of the same family ([@bb0065]) and in tRNA^Ile^ at positions 32 and 33 equivalent to human homoplasmic mutations m. 4090 and m. 4091 reported by [@bb0060] and by [@bb0130] respectively.

In all these mutants we have found respiratory defects mirrored by the inability to grow on respiratory carbon sources. In most cases, the severity of defects paralleled that of the corresponding human diseases. The extent of respiratory defects was also studied by oxygen consumption and by northern blot analysis of charged and uncharged tRNAs; mt protein synthesis products were also analyzed by gel electrophoresis ([@bb0075]).

From the whole of these results a rather clear picture emerged concerning the defects of the various mutants; we also could demonstrate that the nuclear genetic context strongly influenced the phenotypes.

The severity of defects was relieved by the overexpression of EF-Tu ([@bb0025]) and of the cognate aminoacyl-tRNA synthetases ([@bb0015]). Recently, we have demonstrated that suppression also took place when non-cognate aaRS as well as orthologous human enzymes were overexpressed ([@bb0075]). Until now, we have limited our observations to the three mt aaRS, specific for the similar aminoacids leucine, valine and isoleucine, because we are interested in maximizing the similarities which could shed light on the conserved domains that might be involved in suppression.

Yeast mt leucyl-RS (coded by the *NAM2* gene) has been the object of extensive structural studies ([@bb0050; @bb0120]) and the specific function of each domain has been thoroughly analyzed. We could therefore examine the suppressing effect of the multicopy plasmids bearing sequences encoding isolated domains or deleted versions of yeast or human mt LeuRS. Suppression experiments were always performed with all the mentioned mutants and we obtained similar results.

[Fig. 1](#f0005){ref-type="fig"} shows that for mutant LeuC25T the best suppressing activity, similar to that obtained with the complete sequence of the LeuRS gene, is obtained with plasmids containing the carboxy-terminal domain (pΔCP1*NAM2* and Cterm*NAM2*).

Moreover [Fig. 2](#f0010){ref-type="fig"} (panel A) shows that the C-terminal domain of mt LeuRS can suppress the respiratory defects of some other yeast mutants in tRNA^Val^ and tRNA^Ile^. For the IleT32C mutant having the most defective phenotype, the suppression was only obtained when overexpression of the C-terminal domain was induced by galactose.

We then tried to reduce the size of the C-terminal sequence to test whether shorter sequences could maintain the suppressing effect. [Fig. 2](#f0010){ref-type="fig"}, panel B, shows the alignment of human and *S. cerevisiae* mt LeuRS together with the orthologous *Thermus thermophilus* sequence (used for structural studies). Boxes indicate the human LeuRS β-strand sequences contacting the tRNA elbow ([www.expasy.org/spbdv/](http://www.expasy.org/spbdv/)) which we have subcloned in multicopy plasmids.

As indicated in [Fig. 3](#f0015){ref-type="fig"}, the 30_31 and 32_33 fragments from human mt LeuRS had suppressing activity similar to that obtained with the three entire synthetases (Leu-, Val- and IleRS) in relieving the glycerol growth defects of tRNA^Val^ (panel A). The same results were obtained for LeuT25C mutant (not shown) and at 37 °C for the thermosensitive IleT33C mutant (panel B).

The mt localization of proteins encoded in plasmids was controlled by adding the sequence coding for green fluorescent protein (GFP) to the 3′ end of the suppressing sequence and examining cells by fluorescence microscopy. The mt localization of the isolated C-terminal domain shown in [Fig. 4](#f0020){ref-type="fig"} (panel A), might be considered somewhat surprising due to the absence of an mt pre-sequence. However about one half of the over thousand mt nuclearly encoded proteins have been reported to lack a classical import mt pre-sequence ([@bb0005]). On the other side the result of fluorescence microscopy reported in [Fig. 4](#f0020){ref-type="fig"} B shows that similar images can be obtained with the plasmid containing the GFP protein targeted with an mt pre-sequence ([@bb0125]).

In order to rule out the possibility that any high amount of imported protein might have suppressing effect, the aforementioned transformed mutants were also controlled for the glycerol growth phenotype. Results, shown in [Fig. 3](#f0015){ref-type="fig"} (+ pmt*GFP*) clearly demonstrate that the defective growth phenotypes of mutants ValC25T and IleT33C are not rescued.

The suppression effects obtained with the isolated C-terminal domain of LeuRS and with the 30_31 and 32_33 peptides compellingly demonstrate that catalytic function is not necessary for suppression.

Therefore the increased aminoacylation of tRNA^Leu^ in cybrids containing the 3243 MELAS mutation recently observed by [@bb0055] in the presence of the entire mt Lars2 is probably related to the facilitation and stabilization of the correct tRNA folding rather than to increased catalytic activity. By the way this possibility has been proposed by these authors as an alternative explanation.

Analysis of LeuRS ([@bb0045]) had already suggested the hypothesis that the C-terminal domain may function as a general RNA binding domain that enhances interactions with the tRNA substrate. Even, [@bb0035] while examining the evolution of synthetases, have suggested that during the transition from the RNA to the protein world, aaRS might have had a chaperone function to protect the tRNA substrate from destruction by nucleases. These hypotheses might be consistent with our results showing that a short sequence might be responsible for this interaction and explain the suppressing effects we observe.

While the reduced size of suppressing peptides might open the way towards a treatment of mt diseases, several very important problems remain open. Further experiments are obviously necessary to define the extent of cross-suppressing activities (in particular as far as other aaRS and other mutated tRNAs are concerned) and the structural details of the suppressing molecules should be investigated.

At the same time to verify the possible effect of suppressive peptides on cultured cells from patients is obviously an essential step.

Appendix A. Supplementary data {#s0035}
==============================
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![Suppressive effect of the overexpression of *NAM2* and its variants. (A) Serial dilutions of WT (MCC123), of the isogenic LeuC25T mutant and of the same mutant transformed with multicopy empty plasmid and multicopy plasmids bearing the WT *NAM2* gene (coding for *Sc* mt leucyl-tRNA synthetase) or its different variants obtained by deletion or isolation of individual domains as indicated. The tested domains are the CP1 (Connecting Peptide 1 having editing function) and the C-terminal domains. All strains were spotted on YP plate containing 3% glycerol and incubated at 28 °C*.* The same results were obtained at 37 °C. (B) Graphic representation of the results shown in panel A. Values obtained by Phoretix analysis are calculated as percentage of the WT.](gr1){#f0005}

![Suppressive effect of the Cterm*NAM2* domain. (A) Growth phenotype of the WT (MCC123), of isogenic mt tRNA mutants (Val, Leu and Ile), and of the same mutants transformed with the C-terminal domain of LeuRS sequence cloned into the multicopy vector (pCterm*NAM2*) under the inducible GAL1 promoter. The strains were plated on YP 3% glycerol and YP 3% glycerol with addition of 0.1% galactose containing media and grown for three days at 28 °C. (B) Multiple sequence alignment of the C-terminal domain of mt LeuRS (*H. sapiens, Hs*, *S. cerevisiae*, *Sc*, and *T. thermophilus*, *Tt*). Identical aminoacids are highlighted in black; the aminoacids with similar charge are highlighted in gray. The secondary structure elements are indicated by helices (α-helices) and arrows (β-strands). Subcloned sequences contacting the tRNA elbow (<http://www.expasy.org/spbdv/>) are boxed.](gr2){#f0010}

![Suppressive effect of aaRS and parts thereof. (A) Serial dilutions of WT (MCC123), of the isogenic ValC25T mutant, of the mutant transformed with multicopy empty plasmid and multicopy plasmids bearing the *VAS1* gene (coding for *Sc* mt ValRS), the *NAM2* gene (coding for *Sc* mt LeuRS), the *LARS2* gene (coding for *Hs* mt LeuRS), two Cterm*LARS2* variants (30_31 and 32_33) and the *GFP* gene fused to the mt pre-sequence of ATPase subunit 9 of *Neurospora crassa* (pmt*GFP*), as control. The strains are spotted on a YP plate containing 3% glycerol and incubated at 28 °C for three days*.* The same results were obtained at 37 °C. (B) Serial dilutions of the WT (MCC123), of the thermosensitive IleT33C mutant, of the same mutant transformed with multicopy empty plasmid or multicopy plasmids bearing *ISM1* gene (coding for the *Sc* mt Isoleucyl-tRNA synthetase), and other sequences as in panel A were spotted on YP plate containing 3% glycerol and incubated at 37 °C for three days.](gr3){#f0015}

![Cellular localization of LeuRS and its variants. (A) Fluorescence microscopy of ValC25T **(**upper panels**)** and LeuC25T (lower panels) mutants transformed with p*NAM2GFP* and pCterm*NAM2GFP.* The *GFP* gene sequence was cloned in frame at the 3′-end of *NAM2* sequences. As control (bottom panel) the GFP YEAST CLONE (Invitrogen) with the endogenous *NAM2-GFP* fusion. (B) Fluorescence microscopy of WT (MCC123), ValC25T and LeuC25T transformed with a multicopy plasmid bearing the *GFP* gene with the mt pre-sequence of ATPase subunit 9 of *N. crassa* fused at 5′-end (pmt*GFP*).](gr4){#f0020}
